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ABSTRACT  
Aim: The present investigation aimed to analyze clinical and microbiological effects of 
systemic administration of metronidazole and amoxicillin combined with the One-Stage-Full-
Mouth-Disinfection protocol (OSFMD) in generalized aggressive periodontitis patients (G-
AgP). 
Materials and Methods: Thirty-nine systemically healthy patients with G-AgP were 
consecutively included. The test group (n= 19) received amoxicillin-metronidazole 
combination (500 mg of each, three times a day for 7 days) and the OSFMD, the control 
group (n= 20) received the OSFMD and a placebo. In addition to clinical parameters 
subgingival plaque samples from moderate (4-5 mm) and deep (≥ 6 mm) pocket sites were 
analysed for the presence of Aggregatibacter actinomycetemcomitans, Prevotella intermedia, 
Porphyromonas gingivalis, Tannerella forsythia, and Treponema denticola using polymerase 
chain reaction.  
Results: Both therapies led to a statistically significant decrease in clinical and 
microbiological parameters compared to baseline (p<0.001). The most beneficial changes 
were observed in the test group which showed significantly greater improvements in probing 
depth and clinical attachment level and a lower prevalence of Aggregatibacter 
actinomycetemcomitans, Treponema denticola, and Tannerella forsythia compared to the 
control one (p< 0.05).  
Conclusions: Systemic administration of metronidazole and amoxicillin as an adjunct to 
OSFMD therapy significantly improved clinical and microbiological outcomes in patients 
with G-AgP over a 6-month period. 
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Clinical relevance 
Scientific rationale of the study: Adjunctive systemic antibiotics may benefit aggressive 
periodontits patients during non-surgical therapy. No information is available regarding the 
efficacy of systemic antibiotics as an adjunct to OSFMD.  
Principal findings: The administration of systemic amoxicillin/metronidazole in combination 
with OSFMD enhances the efficacy of OSFMD in reducing PD, improving CAL, and in 
decreasing the prevalence of periodontal pathogens especially in initially deep pocket sites.  
Practical implications: These data support the administration of systemic antibiotics during 
the OSFMD protocol in the treatment of generalized aggressive periodontitis patients.  
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INTRODUCTION 
Generalized aggressive periodontitis (G-AgP) is a rapidly progressive disease that affects 
otherwise healthy individuals and results in rapid loss of attachment and bone destruction, 
which may lead to edentulism early in life (Armitage 2004). Therefore, this disease, despite 
its relatively low prevalence in developed countries, has important social implications (Susin 
Albandar & Tinoco 2002, Demmer & Papapanou 2010). The treatment of this condition has 
always represented a challenge for clinicians, because there are no established protocols and 
guidelines for efficiently controlling the disease (Xajigeorgiou et al. 2006). Treatment plans 
have traditionally centred on quadrant scaling and root planing combined with effective 
supragingival plaque control (AAP 2000, Deas & Mealey 2010). However despite this 
therapy some patients may experience ongoing periodontal attachment loss, probably due to 
the persistence of periodontal pathogens and the occurrence of recontamination by pathogens 
residing in other intra- and extradental sites (Danser et al. 1996).  Several studies suggested 
the existence of a translocation of periodontal pathogens from untreated pockets as well as 
from other intra-oral reservoirs such as the tongue dorsum, the mucosa, the saliva and the 
tonsils to treated periodontal sites (Danser et al. 1996, Koshy et al. 2004). In this context, two 
approaches have been introduced to improve the outcomes of non-surgical periodontal 
therapy: the instrumentation of all pockets within a 24-h period in combination with a 
disinfection of intra-oral niches by means of chlorhexidine (CHX) applications (one-stage 
full-mouth disinfection, OSFMD) and the use of adjunctive antibiotics. Despite recent studies, 
performed in chronic periodontitis patients, questioned the advantage of the full-mouth 
disinfection over quadrant scaling (Eberhard et al. 2008, Lang et al. 2008; Teughels et al. 
2009), aggressive periodontitis patients may benefit of this non-surgical approach (Bollen et 
al. 1998, Mongardini et al. 1999, Quirynen et al. 1999, De Soete et al. 2001). Key-pathogens 
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such as Aggregatibacter actinomycetemcomitans, Tannerella forsythia, Treponema denticola, 
Prevotella intermedia and Porphyromonas gingivalis were found to colonize nearly all the 
above-mentioned intraoral reservoirs (Beikler et al. 2004). The relative importance of 
microbial intra-oral translocation in the development and maintenance of periodontal 
infection in G-AgP patients is still undetermined (Koshy et al. 2004).  
Adjunctive antimicrobial therapy with systemic antibiotics kills bacteria out of the range of 
root surface instrumentation and affects periodontal pathogens residing in non-periodontal 
mucosal surfaces (Müller et al. 1998). The recent reports of the European Federation of 
Periodontology and the American Academy of Periodontology suggest that patients with G-
AgP appear to benefit from their adjunctive use (Herrera et al. 2002, Haffajee et al. 2003, 
American Academy of Periodontology 2004, Herrera et al. 2008). Among the possible 
regimens the combination of amoxicillin and metronidazole may be a more effective therapy 
because of the synergistic effect of this combination, and its wide spectrum of activity 
(Pavicic et al. 1994, Guerrero et al. 2005, Xajigeorgiou et al. 2006, Herrera et al. 2008, 
Mestnik et al. 2010). This is of particular importance in G-AgP patients who yielded a high 
prevalence of Aggregatibacter actinomycetemcomitans and anaerobic pathogens in 
subgingival microbiota (Ishikawa et al. 2002, Lee et al. 2003, Takeuchi et al. 2003, Kamma et 
al. 2004, Faveri et al. 2008). Previous investigations demonstrated that suppression of these 
bacteria below the detection level results in remarkable improvement in clinical parameters 
(Haffajee et al. 1997, Winkel et al. 1998).  
To the best of our knowledge a limited number of randomized controlled clinical trials 
focused on the additional effects of adjunctive amoxicillin-metronidazole in the non-surgical 
treatment of G-AgP patients (Guerrero et al. 2005, Xajiegeorgiou et al. 2006, Kaner et al. 
2007a, Yek et al. 2010, Mestnik et al. 2010) and no information is available regarding the 
added benefits to the OSFMD. Thus, the aim of the present investigation was to evaluate the 
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adjunctive clinical and microbiological effects of the administration of amoxicillin and 
metronidazole in the OSFMD protocol in G-AgP patients.  
MATERIALS AND METHODS 
Study design 
The present study was a randomized, double-blind, placebo-controlled, single centre, 6-month 
clinical trial. Research was conducted according to the principles outlined in the Declaration 
of Helsinki on experimentation involving human subjects. The protocol was approved by the 
Ethics Committee of the University of Turin, Italy. All patients were informed individually 
about the nature, potential risks and benefits of the proposed treatment and signed informed 
consent forms. 
Population screening 
Consecutive patients from those referred for treatment to the Division of Periodontology, 
Dental School, University of Turin, were recruited after a screening examination that included 
a full medical and dental history, intraoral examination, full-mouth periodontal probing and 
radiographs. Subjects who were invited to participate met the inclusion criteria of G-AgP 
described by Armitage (1999), as follows: 1) good general health; 2) generalized 
interproximal attachment loss involving at least 3 teeth apart from molars and first incisors; 3) 
amount of microbial deposits inconsistent with the severity of periodontal tissue destruction;  
4)  familial aggregation (during the anamneses patients were asked whether at least one 
member of the family presented with a history of periodontal disease).  
In addition all patients had to present with a minimum of 20 teeth excluding teeth indicated 
for extraction and ≥ two sites around  at least 12 teeth  with  clinical attachment level (CAL) 
and probing depth ≥ 6 mm. Exclusion criteria included: smoking habits, medical disorders 
that require prophylactic antibiotic coverage or that could influence the progression or 
treatment of periodontitis (i.e. diabetes mellitus, autoimmune dysfunctions, bone metabolic 
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diseases); consumption of drugs known to affect periodontal status (anticonvulsants, 
immunosuppressant, calcium channel blockers); antibiotic therapy within the last 6 months; 
long-term administration of anti-inflammatory medications; allergy to penicillin and/or 
metronidazole; periodontal treatment in the previous 6 months; pregnancy and lactation. Each 
accepted participant received a patient number in ascending order.  
Sample size calculation 
According to a systematic review (Herrera et al. 2002) adjunctive systemic antibiotics may 
result in additional reduction of approximately 0.5 mm for mean full-mouth PD when 
compared to scaling and root planning (SRP) alone. Thus, a difference of 0.5 mm between 
groups for mean full-mouth PD reduction after 6 months was considered to be clinically 
relevant. The sample size calculation determined that 17 subjects per treatment group would 
provide 80% power to detect a true difference of 0.5 mm between test and placebo, assuming 
0.5 mm as the common standard deviation. To compensate for possible drop-outs 21 patients 
were recruited per treatment group.  
Randomization and allocation concealment 
Before the first session of the OSFMD, subjects were randomly assigned by a computer-
generated list to receive one of the two treatments (OSMFD and systemic antimicrobials or 
OSFMD and placebo). A balance random permuted block approach was used to prepare the 
randomization tables in order to avoid unequal balance between the two treatment groups. 
Allocation was implemented by a person not involved in the study.  Using this list, treatment 
assignments were distributed to numbered opaque envelopes. The plastic bags containing two 
identical opaque bottles each (19 bottles with amoxicillin 500 mg, 19 with metronidazole 500 
mg, 20 with amoxicillin placebo and 20 with metronidazole placebo) were sent to the 
clinician responsible for the research (M.A.). He opened the sealed envelope and marked the 
subject number on the neutral bottles containing the test or the placebo medications. The 
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plastic bags were given by a study assistant to each patient. The treatment codes of the study 
were not available to the treating investigator and to the examiner until the data were analysed 
by the statistician.  
Clinical measurements  
Clinical recordings were performed by one masked and calibrated examiner (F.R.) using a 
standardized periodontal probe with 1-mm markings (PCP-UNC 15, Hu-Friedy, Chicago, IL, 
USA), and rounded up to the nearest mm. The following parameters were assessed at six sites 
around all present teeth: presence/absence of plaque (IP), presence/absence of bleeding on 
probing (BOP), probing depth (PD), recession of the gingival margin (REC), and CAL, 
defined as the algebraic sum of PD and REC. The percentages of total surfaces which 
revealed the presence of plaque or BOP within each subject were expressed as full mouth 
plaque score (FMPS) and full mouth bleeding score (FMBS). 
Examiner calibration 
A total of 6 non-study patients with G-AgP were recruited for the calibration exercise. The 
single designated examiner (F.R.) recorded full-mouth PD and REC with an interval of 24 h 
between the first and the second recording. The intra-examiner repeatability for CAL was 
measured. The K coefficient (± 1 mm) was 0.93. 
Microbiological examination  
Subgingival plaque samples were collected at 4 sites, 2 with moderate PD (4-5 mm) and the 
other 2 with severe PD (≥ 6 mm), with no endodontic or furcation involvement. Periodontal 
sites for bacterial sampling were randomly selected.  After isolating with cotton rolls, drying, 
and removal of supragingival plaque, subgingival samples were taken by inserting two sterile 
paper points into the apical extent of each selected pocket, placed in a sterile Eppendorf tube 
containing 1 ml of a prereduced transport medium (Ringer solution) and sent to the laboratory 
of the Department of Microbiology. After centrifugation for 1 min at 12,000 g the supernatant 
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was removed and the pellets were stored at –20°C until processing and analysis by 
polymerase chain reaction (PCR). The microbiologist who performed analysis of subgingival 
samples was not aware of the treatment that the patient had received (coded samples). The 
PCR procedures were described in a previous report (Aimetti et al. 2007). Primers for 
Aggregatibacter actinomycetemcomitans, Tannerella forsythia, Prevotella intermedia, 
Treponema denticola, and Porphyromonas gingivalis were designed on the basis of 16S 
rRNA sequence by Ashimoto et al. (1996). PCR amplification products were analyzed by 2% 
agarose gel electrophoresis in Tris-borate EDTA buffer. The gel was stained with ethidium 
bromide (0.5µg/ml), and photographed under a UV light transilluminator (Becton, Dickinson, 
Franklin Lakes, NJ, USA). Species-specific primers were previously tested for cross-
reactivity with other closely related species by Ashimoto et al. (1996).  In addition, all primer 
sequences were compared with the GenBank to further ensure their specificity. The PCR 
detection limit was 10 genome equivalents. 
Non-surgical treatment 
After an initial screening visit for recruitment, all patients underwent a session of 
supragingival scaling and polishing and received instructions in proper self-performed plaque 
control measures, including special instructions in the Bass technique and interproximal 
cleaning with dental floss and interdental brushes. They were also motivated to brush the 
tongue dorsum once a day. At the end of the session, baseline clinical measurements were 
recorded except for both plaque index and bleeding index that were assessed immediately 
prior to scaling. One week later, patients were subjected to OSFMD according the protocol by 
Quirynen et al. (1995) modified by Bollen et al. (1998). Full-mouth subgingival SRP were 
performed in two sessions within 24 h by a single experienced therapist (G. N.) using hand 
instruments (Gracey curettes, Hu-Friedy) and ultrasonic scalers (Cavitron Select, Dentsply, 
York, PA, USA). The therapist was blinded to the treatment assignment. Subgingival 
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instrumentation was performed under local anesthesia without a time limit until the root 
surface felt smooth and clean to an explorer tip. Mechanical debridement was supplemented 
by the disinfection of intra-oral niches. Immediately after each instrumentation session the 
dorsum of the tongue was brushed by the patient with a 1% CHX gel for 1 min (Corsodyl® 
gel, GlaxoSmithKline Consumer Healthcare, Baranzate di Bollate (MI), Italy), the mouth was 
rinsed twice with a 0.2% CHX solution for 1 min (Corsodyl® mouthrinse), the farynx was 
sprayed (4x tonsil) with  a 0.2% CHX spray (Corsodyl® spray), and all pockets were irrigated 
(3 times within 10 min) with a 1% CHX gel. This subgingival application was repeated 8 days 
after. Test and control subjects were instructed to use a 0.2% CHX rinse twice a day for 1 min 
and to spray the tonsils twice daily with a 0.2% CHX for 2 months post-treatment. All 
patients were provided with both 0.2% CHX solution and spray to use during the 
experimental period.  
The CHX rinses and the antibiotic and placebo therapies started immediately after the first 
session of OSFMD. Test subjects received systemic antibiotics (amoxicillin 500 mg and 
metronidazole 500 mg), while control subjects received the placebo medications. All subjects 
were advised to use placebo or antibiotic three times a day for 7 days (Guerrero et al. 2005, 
Yek et al. 2010).  
Evaluation of adverse events and compliance 
The study assistant called each subject every two days by telephone to remind him to take the 
placebo or antimicrobial medications. Adverse effects and compliance with medication intake 
were recorded by the same study assistant not involved in the randomization process. Subjects 
were asked to return the bottles of medications the day after the last capsule had been taken 
and the missing capsules were registered. At the same time subjects were asked to answer a 
questionnaire about any side effect that could be associated with the medication/placebo 
intake. Compliance with the use of CHX was evaluated at each visit scheduled during the first 
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2 months post-operatively. The study assistant recorded the presence of CHX staining on both 
teeth and tongue dorsum according to the criteria of the stain index described by Lobene 
(1968). CHX staining was eliminated by polishing at each session.  
Post-treatment controls 
During the post-treatment appointments, the patients’ oral hygiene standards were reviewed 
and oral hygiene procedures were reinforced. Moreover, all patients received full-mouth 
supragingival debridement and professional tooth cleaning. No subgingival instrumentation 
was performed until the end of the study in order to not interfere with subgingival microbiota. 
The appointments were on a 2-week interval during the first 6 weeks post-operatively and 
every 2 months up to the 6-month evaluation.  
Re-assessment examinations 
Full-mouth clinical examination was performed at 3 and 6 months after the completion of the 
second session of OSFMD. During these appointments the clinical periodontal parameters 
assessed at baseline were recorded again. Bacterial sampling was repeated at 15 days, 3 
months and 6 months. 
Statistical analysis   
The primary outcome measure of the study was reduction in mean full-mouth PD values.  
Secondary outcomes included reduction in mean CAL, decrease of FMPS and FMBS values, 
reduction in PD values at different initial PD categories, decrease of the proportion of sites 
with PD ≥ 5 mm, change of proportions of moderate and deep sites harbouring periodontal 
pathogens. 
For clinical parameters a mean value per patient and per follow-up moment was calculated in 
order to maintain the patient as the statistical unit. The balancing of experimental groups by 
demographic and clinical parameters was tested by Student’s t-test (age, PD, CAL, number of 
sites with PD ≥5 mm) and the Mann-Whitney U test (FMPS, FMBS). The groups were 
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compared with respect to categorical variable using the chi-square analysis (gender, ethnicity). 
To test the effect of time and treatment on response variables within each group the repeated 
measures of analysis of variance (PD, CAL, number of sites with PD ≥5 mm) and the 
Friedman’s test (FMPS, FMBS) were used. Multiple comparisons were conducted with the 
post-hoc tests (Newman-Keuls test and Dunn test). The proportions of sites with PD ≥ 5 mm 
were analysed by the chi-square test.  
Subsequently the Student’s t-test for independent samples and the Mann-Whitney U test were 
used for pairwise comparisons between the groups. For categorical data the chi-square test 
was applied. The Bonferroni correction was used to confirm any significant values arising 
from multiple comparisons.  
As further analysis the changes in PD and CAL in initially moderate (4-5 mm) and deep  (≥ 6 
mm) pocket sites were calculated and tested to explore intra- and inter-treatment differences 
by parametric methods (ANOVA, Newman-Keuls post hoc test and Bonferroni-corrected t-
test for independent samples). 
Finally, microbiological data were analyzed with the subject and the site as the observational 
unit. The number of subjects positive for the investigated species were calculated at baseline, 
15 days, 3 and 6 months after treatment. The patient was scored positive for a microorganism 
if at least one out of the four sampled sites harbored this microorganism. The prevalence of 
the five pathogens was analyzed separately in sites with moderate and severe PD. When the 
PCR did not detect bacteria, the value for the statistical evaluation was zero. Microbiological 
data were analyzed by applying the chi-square test except when expected counts were less 
than five where the Fisher’s exact test was used. An experimental level of significance (alpha) 
was set at 0.05. 
Results  
The flow chart of the experimental design is presented in Fig. 1. Sixty-six subjects were 
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assessed for their eligibility from January 2009 to February 2010. Of these, 24 were excluded: 
20 did not meet the inclusion criteria, while the other 4 refused to participate. Forty-two 
subjects were enrolled in the study. Three patients had to be excluded after enrolment. Two 
subjects did not return to the pre-treatment session of supragingival scaling and polishing for 
unknown reasons and one subject dropped out of the study at the same appointment due to 
antibiotic intake for unrelated systemic illness. Random assignment resulted in 39 patients (20 
in the placebo group and 19 in the test group).  
Table 1 summarizes the demographic characteristics and Tables 2 and 3 present the mean full-
mouth values for the clinical parameters at baseline, 3 and 6 months after therapy. There were 
no relevant differences between test and placebo group at baseline relative to gender, age and 
ethnic distribution. There were also no statistically significant differences in clinical 
parameters (p>0.05).  
Clinical results  
Regarding compliance with medication intake, all participants returned the bottles and a 
100% compliance was achieved. No serious adverse effects were observed or reported from 
antibiotic intake other than a mild gastrointestinal discomfort in three subjects. None had to 
stop the intake of medications. All test and placebo patients had similar amount of CHX 
staining at the end of each scoring visit.  Dental stain of light to moderate intensity was 
observed on the buccal surfaces of incisive, canine and premolar teeth and covered one-third 
to two-thirds of the surface area. Similar findings were seen when considering tongue stain. 
Full mouth plaque score and FMBS decreased significantly in both groups at the end of 3 and 
6 months compared to baseline values (p<0.001, Table 2). Plaque scores remained below 15% 
during the experimental phase in both groups (p < 0.001). Between-group analysis at each 
time point did not indicate relevant differences. When analysing FMBS, the improvement was 
greater in the test group.  At 3 months after therapy 9.3% and 16.6% of the sites in the test 
15 
 
and control groups, respectively, exhibited BOP (p< 0.001). The percentages remained fairly 
unchanged at 6 months.  
As reported in Table 3, both therapies led to a statistically significant decrease in overall mean 
PD and CAL at 3 and 6 months compared to baseline (p< 0.001). The greatest reduction in the 
mean PD occurred during the first 3 months after treatment, whereas no further significant 
changes were observed within the treatment groups between 3 and 6 months (p>0.05). After 6 
months the mean PD reduction and the mean clinical attachment gain amounted to 1.6 ± 0.5 
mm and 1.4 ± 0.6 mm, respectively, in the test group and to 1.2 ±0.3 and 1.0 ± 0.3 mm, 
respectively, in the placebo group. The differences between treatment modalities were 
statistically significant at months 3 (PD, p=0.015) and 6 (PD, p= 0.01 and CAL, p= 0.01) 
favouring the test group.  An adjunctive benefit of 0.4± 0.1 mm for PD reduction was 
observed in the amoxicillin-metronidazole group at 3- and 6- month examinations compared 
to baseline (p0-3=0.009, p0-6=0.004) and of 0.4 mm ± 0.2 for CAL changes at 6 months (p0-
6=0.01).  
A separate analysis of initially moderate (4-5 mm) and deep (≥ 6 mm) pocket sites was 
performed. Within the treatment groups significant PD and CAL changes were found over the 
course of the study in both moderate and deep pocket sites  (p<0.001). At moderate pockets, 
differences between treatment groups reached statistical significance only for clinical 
attachment gain at 6-month evaluation (p=0.009). At pockets initially ≥ 6 mm PD reduction 
and clinical attachment gain were significantly greater in test subjects at both 3- and 6-month 
examination.  At 3 months the difference between test and placebo treatment was of 0.6 mm 
for PD reduction (p=0.004) and of 0.8 mm for CAL changes  (p<0.001). These values were 
maintained at 6 months.  
Regarding both the number and the proportion of sites with PD ≥ 5 mm, a statistically 
significant greater decrease was observed in the amoxicillin-metronidazole group in 
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comparison with the placebo group over the course of the study (p<0.001). At baseline 
subjects in the test group had an average of 92.2 ± 25.1 sites with PD ≥ 5 mm and subjects in 
the placebo group had 89.3 ± 22.4 sites in this category. At 3 months the average number of 
such sites was 29.7 ± 8.1 per patient in the test group compared to 48.3 ± 14.7 in the control 
one.  These values were fairly unchanged at 6 months  (28.3 ± 7.7 in the test group versus 
46.2 ± 13.4 in the placebo group). When considering the proportion of sites with PD ≥ 5 mm, 
at baseline 56.6% of the test sites had PD ≥ 5 mm and 54.9 % of the control sites did. At 3-
month evaluation residual PDs ≥ 5 mm were observed in 18.6% of the test sites compared to 
29.7% of the control sites. These values were maintained at 6 months  (17.7% in the test 
group versus 28.4% in the control one).  
Microbiological observations 
Change in the prevalence of bacterial species 
Table 4 presents the frequency of subjects colonized by the five target periodontal pathogens 
over the 6-month period in the two treatment groups. Even though no differences in the 
detection frequencies of all bacterial species were observed between the two groups at 
baseline, the test group showed a significantly greater decrease in the percentage of patients 
colonized by both A. actinomycetemcomitans and the red complex species in comparison with 
the control group. No difference was observed between the two treatment groups for P. 
intermedia at any time point (p>0.05). The greatest decrease was observed for A. 
actinomycetemcomitans. At 6 months after treatment three subjects in the test group tested 
positive for this species compared to 13 subjects in the control group (p=0.005).   
Figure 2 and Figure 3 summarize the number of moderate and deep sampled pockets that 
harboured the target species at each time point. During the experimental period the 
combination OSFMD and antibiotic intake was more effective than OSFMD and placebo in 
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decreasing the number of sites positive for all the monitored species. The difference between 
test and placebo groups was statistically significant at 6-month evaluation for moderate 
pockets and at 3 and 6 months for deep pockets sites. With regard to 4-5 mm sampled pockets 
25 (65.8%) test sites compared to 15 (37.5%) control sites were free of pathogens at 6 months 
(p< 0.001). Among pockets initially ≥ 6 mm 26 (68.4%) and 22 (57.9%) test sites were free of 
pathogens at 3 and 6-month examination compared to 14 (35%) and 6 (15%) control sites, 
respectively (p= 0.01 at 3 months and p < 0.001 at 6 months).  
When analyzing the pattern of each bacterial species, the administration of antimicrobials 
resulted in the elimination of A. actinomycetemcomitans at both moderate and deep sites 15 
days after the second session of the OSFMD. No significant differences were observed 
between treatments in the prevalence of P. intermedia, P. gingivalis, T. forsythia and T. 
denticola at this time point neither in moderate nor in deep sites (p >0.05). Six months from 
baseline a recolonization or regrowth of all the investigated species was noted. At moderate 
sites (Figure 2) no differences were detected between groups (p>0.05) with the exception of 
A. actinomycetemcomitans  that was isolated in 5.3% of test sites compared to 35% of the 
control ones (p=0.02). At deep sites (Figure 3) the combined therapy was more efficient than 
OSFMD and placebo to achieve a lower prevalence of A. actinomycetemcomitans and T. 
denticola at 3 (p= 0.03 and p= 0.04, respectively) and 6 months (p= 0.02 and p= 0.03, 
respectively), and of T. forsythia at 6-month examination (p= 0.04). The proportions of P. 
gingivalis and P. intermedia were not significantly lower in the test sites than in the placebo 
sites at any time point (p>0.05).   
Discussion 
The OSFMD has been proposed as a therapeutic approach particularly indicated for patients 
who experienced advanced and rapidly progressing periodontal diseases (Quirynen et al. 
2006, Teughels et al. 2009). Its benefits could become more significant with the adjunctive 
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administration of systemic antibiotics. The unavailability of guidelines for the use of 
systemically administered antimicrobials in G-AgP patients have led to conflicting decisions 
on the selection of different therapeutic approaches (Herrera et al. 2008, Shaddox & Walker 
2009).  
In the current study we evaluated the 6-month clinical and microbiological effects of systemic 
amoxicillin-metronidazole or placebos combined with the OSFMD protocol (Quirynen et al. 
1995, Bollen et al. 1998). Our data indicated that the adjunctive antimicrobial therapy 
achieved significantly greater improvement in clinical parameters than OSFMD and placebo. 
At 6 months patients who took systemic antibiotics presented a lower percentage of bleeding 
sites, a greater reduction in full-mouth PD, and fewer sites with PD ≥ 5 mm in comparison 
with the placebo group. It is important to point out that plaque levels were maintained at a low 
level (< 15%) through the study period in both treatment groups, indicating both good oral 
hygiene performance of all patients and successful re-motivation during post-treatment 
controls. Recall appointments for reinforcement of oral hygiene measures and supragingival 
professional debridement were scheduled every two weeks during the first 6 weeks and at 2-
month interval up to the 6-month evaluation. This protocol might be relevant to the reduction 
of plaque because full-mouth instrumentation is performed in two visits and thus the therapist 
has fewer opportunities to deliver, check, and reinforce the necessary oral hygiene 
instructions (Teughels et al. 2009). Moreover, in according to the full-mouth disinfection 
approach (Quirynen et al. 1995), patients had not to reach an appropriate level of plaque 
control before receiving the first session of OSFMD.  
The results obtained in the control group were within the range expected from the OSFMD in 
aggressive periodontitis patients (Mongardini et al. 1999, Aimetti et al. 2011). Six months 
after this non-surgical approach the mean full-mouth PD reduction was 1.2 mm and the mean 
full-mouth clinical attachment gain amounted to 1.0 mm. At this time the mean PD reduction 
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was 1.4 mm and 2.4 mm for initially moderate and deep pockets, respectively. These results 
are better or comparable to those reported after conventional SRP in G-AgP patients with 
similar baseline mean PD.  Hughes et al. (2006) reported a mean full-mouth PD reduction of 
0.4 mm at 10 weeks, whereas Rosalem et al. (2011) and Xajigeorgiou et al. (2006) of 0.69 
mm at 3 and 6 months, respectively. Sigush et al. (2001) showed that in pockets initially >6 
mm a 2.3 mm PD reduction was achieved 6 months after treatment.  
The clearest advantage of antibiotics over placebo was noted on inflammatory values and in 
pockets initially ≥ 6 mm. In the test group the FMBS remained below 10%, whereas in the 
control group the percentage ranged between 12% and 20% over all the experimental period. 
In deep pocket sites the test treatment resulted in additional 0.7 mm in mean PD reduction and 
1.00 mm in clinical attachment gain, while not statistically significant differences were 
observed in moderate periodontal sites. At 6 months post-therapy the proportion of sites with 
PD ≥ 5 mm was 17.7% in the test group compared to 28.4% in the placebo group. As 
previously demonstrated the effect of the antibiotics was particularly evident at deeper 
pockets where mechanical debridement was less effective (Guerrero et al. 2005).   
Only a few randomized controlled clinical trials focused on the additional effects of 
adjunctive amoxicillin-metronidazole in the therapy for well-defined G-AgP in patients with 
severe disease (Guerrero et al. 2005, Xajiegeorgiou et al. 2006, Kaner et al. 2007a, Moreira & 
Flores-Filho 2007, Mestnik et al. 2010, Yek et al. 2010, Griffiths et al. 2011). In these reports 
the combination of antimicrobials with quadrant or full-mouth SRP resulted in average  
values of 1.2-1.6 mm for PD reduction and of  0.5-1.3 mm for CAL gain over a 3- or 6-month 
period. A direct comparison of these measures of clinical outcomes is unfeasible because of 
discrepancy among study designs, especially regarding the schedule for debridement, time of 
clinical measurements, dosage and timing of drug administration. The variation between 
studies concerning the time of antimicrobials administration is noticeable, as medication was 
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started simultaneously with SRP (Guerrero et al. 2005, Yek et al. 2010, Mestnik et al. 2010), 
1 week (Kaner et al. 2007a), 6 weeks after SRP had been completed (Xajiegeorgiou et al. 
2006) and during re-treatment (Griffiths et al. 2011). Recent investigations report greater 
clinical improvements when the adjunctive agent is used concomitantly with non-surgical 
treatment (Kaner at al. 2007b, Griffiths et al. 2011).  In the present investigation the 
administration of antibiotics started on the same day of full-mouth periodontal 
instrumentation, signifying that all quadrants were equally benefited by the antimicrobial 
therapy. This eliminates the problem associated with the timing of drug administration during 
quadrant-wise SRP (Killoy 2002).  
In the present study we prescribed 500 mg of both antibiotics three times a day for 7 days. 
This dosage had been reported in recent randomized controlled clinical trials (Guerrero et al. 
2005, Xajiegeorgiou et al. 2006) to reach and maintain effective antimicrobial concentration 
in body fluids (Winkel et al. 1998). Previous studies which used a moderate dose of 
metronidazole (250 mg) combined with 500 mg of amoxicillin reported lack of significant 
adjunctive benefits over SRP alone (Heller et al. 2011).   
No serious adverse effects were reported from antibiotic intake other than a mild 
gastrointestinal discomfort in three subjects (16%). This was in agreement with the results of 
previous investigations (Xajiegeorgiou et al. 2006, Mestnik et al. 2010).  
The clinical outcomes were supported by the microbiological findings. The baseline profile 
was comparable in both treatment groups and was consistent with data reported in the 
literature (Mullally et al. 2000, Albandar et al. 1997, Kamma et al. 2004, Xajigeorgiou et al. 
2006), except for the lower prevalence by Kamma et al. (2004) for A. actinomycetemcomitans 
in G-AgP patients of Greek origin. Several papers have suggested varying species dominating 
the microbiota of G-AgP patients, according to the ethnicity (Rylen & Kilian 2008). The 
systemic administration of amoxicillin-metronidazole was more effective in decreasing the 
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number of sites positive for all the monitored species than OSFMD alone. In the test group all 
the target bacteria were suppressed below the detection level in 65.8% and 57.9% of moderate 
and deep sites, respectively, at 6-month evaluation. While, the percentage of moderate and 
deep sites free of pathogens amounted to 37.5% and 15% in the control group at the same 
time point (p<0.001).  
When individual species were analysed the most significant difference between the combined 
therapy and the OSFMD alone was the pronounced effect of the antibiotic combination on A. 
actinomycetemcomitans. Previous investigations on the effects of SRP and OSFMD on the 
subgingival microflora reported conflicting results about the ability to eradicate or suppress 
important periodontal pathogens. T. forsythia and especially A. actinomycetemcomitans have 
been shown to remain in periodontal pockets after non-surgical therapy (Takamatsu et al. 
1999, Mombelli et al. 2000, Koshy et al. 2005). Therefore, the combination of amoxicillin and 
metronidazole was originally proposed for the elimination of A. actinomycetemcomitans (van 
Winkelhoff et al. 1989). In the present investigation, A. actinomycetemcomitans was 
eliminated from 10 subjects in the test group and from 2 subjects in the control group at 6 
months post-therapy. When bacterial samples were analysed according to initial PD 
categories, the test group showed complete suppression of A. actinomycetemcomitans 15 days 
following treatment and  recolonization  by this species in  5.3% and 7.9% of initially 
moderate and deep periodontal pockets, respectively, at 6 months. Few studies have evaluated 
the added effects of high dosage of amoxicillin-metronidazole on the subgingival microbiota 
of G-AgP patients. They reported complete suppression of A.actinomycetemcomitans in four 
subjects at 3 months post-therapy (Mestnik et al. 2010) or in one subject at 6-month 
evaluation (Xajiegeorgiou et al. 2006). The variations in the complexity of the subgingival 
microbiota (Haffajee et al. 2005) as well as in the antibiotic susceptibility of periodontal 
pathogens in distinct geographic locations (van Winkelhoff et al 2005) might in part explain 
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the differences in the effectiveness of systemic antimicrobials. 
In contrast to the findings of Yek et al. (2010) who reported eradication of T. forsythia in the 
test group after SRP and a 7-days course of  systemic metronidazole (500 mg, tid) and 
amoxicillin (500 mg, tid), in the current investigation the combined therapy was unable to 
completely eliminate T. forsythia in both moderate and deep sites.  Nevertheless, it prevented 
its tendency to increase over the 6- month period in deep sites when compared to the control 
group. No differences between the two treatment groups were observed at pockets initially 4-
5 mm deep. A similar pattern was observed for T. denticola. 
The prevalence of sampled sites colonized by P. gingivalis and P. intermedia  was not 
significantly lower in the test group than in the OSFMD group neither at 3- nor at 6-month 
examination. Our data are in agreement with the findings by Yek et al. (2010) and Heller et al. 
(2011) who reported a reduction in the level of P. gingivalis over a 6-month period but they 
did not detect any difference between the treatment groups.  It is interesting to point out that 
when a per-patient analysis was performed a significant difference was detected in the 
proportion of subjects positive for P. gingivalis between the two treatment groups. At 6-
month examination 6 subjects in the test group in comparison with 14 subjects in the placebo 
group were colonized by this periodontal pathogen. In addition test subjects who tested  
positive for P. gingivalis presented this species in 2 (four subjects) and 3 (two subjects) 
sampled sites. Differences in host response, in bacterial susceptibility to antibiotic agents and  
in bacterial clones could partly account for variations of treatment efficacy.  
A shortcoming of the present investigation was the evaluation of the adherence to 
antibiotic/placebo medications. Patients were asked to return the bottles of medications the 
day after the intake of the last capsule and the remaining pills were counted (Guerrero et al. 
2005, Heller et al. 2011, Griffiths et al. 2011). Guerrero et al. (2007) reported that this way of 
monitoring patients compliance may underestimate non-adherence or partial adherence. Thus, 
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we called patients every two days to remind them to take the placebo or antimicrobial 
medications (Haas et al. 2008, Mestnik et al. 2010).     
Another aspect to be considered is the lack of microbiological entry criteria. In agreement 
with previous investigations the antibiotic regimen was applied empirically (Mombelli 2005, 
Heller et al. 2011, Mestnik et al. 2010). It is interesting to point out that as previously reported 
by Yek et al. (2010) in the present investigations G-AgP patients presented at baseline 
comparable frequency of detection of the five periodontal pathogens. In addition, the 
percentage of patients positive for A. actinomycetemcomitans was high. In such patients, as 
previously reported by Xajigeorgiou et al. (2006), the addition of amoxicillin enhances 
clinical as well as microbiological effects of metronidazole alone.  
In conclusion, the OSFMD represents a viable approach to deal with G-AgP patients. When 
combined with systemic amoxicillin plus metronidazole it resulted in statistically significantly 
greater improvement in FMBS, reduction in full-mouth PD and decrease in the number of 
sites with PD ≥ 5 mm. These observations were valid for both 3- and 6-month evaluations 
after the completion of active treatment. Clinical results are supported by microbiological 
findings.  
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Table 1. Demographic characteristics at baseline (mean ±  SD)  
Parameter Test group (n=19) Placebo group (n=20) Difference between groups  
P-value 
 
Age (years) 36.3 ± 3.2 35.7 ± 2.8 NS* 
Females (%) 58 50   NS** 
Caucasians (%)   79     85   NS** 
NS=difference between groups is not statistically significant (P>0.05) 
* T-test for independent samples  **Χ2- test 
 
Table 2. Changes of FMPS and FMBS at baseline, 3 and 6 months 
Clinical parameter Group Baseline 3 months 6 months 
 
FMPS (%) 
 
Test 
 
59.7 ± 19.0* 
 
12.8 ± 2.1** 
 
13.0 ± 1.6** 
 Placebo 60.4 ± 27.1* 12.6 ± 2.4** 12.1 ± 2.1** 
Differences between groups       NS† NS‡ NS‡ 
 
 
FMBS (%) Test  61.5 ± 17.7* 9.3 ± 0.8**  9.4 ± 0.6** 
 Placebo 56.2± 18.2* 16.6 ± 5.0** 15.5 ± 3.8** 
Differences between groups  NS† P<0.001‡ P<0.001‡ 
 
 
FMPS full-mouth plaque score; FMBS full-mouth bleeding score 
NS=difference between groups is not statistically significant (P>0.05) 
*P<0 .001; p-values represent changes among the three time points (Friedman’s test) 
**P<0.001 p-values represent longitudinal changes from baseline (Dunn test) 
†Mann-Whitney U test; ‡Bonferroni-corrected Mann-Whitney U test. 
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Table 3. Changes (mean ±  SD) of probing depth and clinical attachment level  
          Variable  Group Baseline 3 months Δ0-3 months  6 months Δ0-6 months 
 
Full-mouth PD (mm)  
 
Test 
 
4.3 ± 1.1* 
 
2.8  ± 0.6 
 
1.5 ± 0.5** 
 
2.7  ± 0.6 
 
1.6 ± 0.5** 
 
 Placebo 4.5 ± 1.1*    3.4 ± 0.8 1.1 ± 0.4**    3.3 ± 0.8 1.2 ± 0.3** 
Difference between groups  NS P=0.015§  P=0.01§ 
 
 
 
 PD (mm) at sites with 
initial pockets 4-5 mm  
 
Test 
 
4.7 ± 0.2* 
 
3.0  ± 0.3 
 
1.7 ± 0.3** 
 
2.9  ± 0.5 
 
1.8 ± 0.3** 
 Placebo 4.4 ± 0.1*    2.9 ± 0.3 1.5 ± 0.3**    3.0 ± 0.4 1.4 ± 0.3** 
Difference between groups  NS NS§  NS§ 
 
 
       
PD (mm) at sites with initial 
pockets ≥  6 mm  
Test 6.9 ± 0.7* 3.8 ± 0.4 3.1 ± 0.7** 3.8 ± 0.8 3.1 ± 0.6** 
 Placebo 7.1 ± 0.6* 4.6 ± 0.7 2.5 ± 0.5** 4.7 ± 0.8 2.4 ± 0.7** 
Difference between groups  NS P=0.004§  P=0.003§ 
 
 
 
Full-mouth CAL (mm) Test 4.7 ± 1.1* 3.4 ± 0.8  1.3 ± 0.5**  3.3 ± 0.6 1.4 ± 0.6** 
 
 Placebo 5.0 ± 1.2*    4.0 ± 1.1   1.0 ± 0.3**  4.0 ± 1.0 1.0 ± 0.3** 
Difference between groups  NS NS§  P=0.01§ 
 
 
 
CAL (mm) at sites with 
initial pockets 4-5 mm 
Test 5.0 ± 0.4* 3.5 ± 0.4  1.5 ± 0.3**  3.4 ± 0.4 1.6 ± 0.3** 
 Placebo 4.8 ± 0.5*    3.4 ± 0.4   1.4 ± 0.4**  3.8 ± 0.5 1.0 ± 0.4** 
Difference between groups  NS NS§  P=0.009§  
 
       
CAL (mm) at sites with 
initial pockets ≥  6 mm 
Test 7.7 ± 0.7* 4.7 ± 0.6 3.0 ± 0.7** 4.7 ± 0.8** 3.0 ± 0.7** 
 Placebo 7.8 ± 0.6* 5.6 ± 0.8 2.2 ± 0.7** 5.8 ± 1.0** 2.0 ± 0.8** 
Difference between groups  NS P<0.001§  P<0.001§  
       
PD probing depth; CAL clinical attachment level 
NS=difference between groups is not statistically significant (P>0.05) 
*P<0 .001; p-values represent changes among the three time points (ANOVA) 
**P<0.001 p-values represent longitudinal changes from baseline (Newman-Keuls test) 
§Bonferroni-corrected t-test  
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Table 4. Number (percentage) of patients positive for the five periodontal pathogens at 
various time points (Χ2 –test). 
 Group Baseline 15 days after 
OSFMF 
3 months 6 months 
      
A. actinomycetemcomitans Test 13 (68.4) 0* 2 (10.5)*  3 (15.8)** 
 Placebo 15 (75.0) 7 (35.0)§ 8 (40.0)# 13 (65.0)# 
Differences between groups  NS P=0.008 P=0.04 P=0.005 
 
P. intermedia Test 13 (68.4) 3 (15.8)**  4 (21.1)** 5 (26.3)§ 
  12 (60.0)          4 (20.0)§ 5 (25.0) § 7 (35.0)# 
Differences between groups  NS NS NS NS 
 
P. gingivalis Test 14 (73.7) 3 (15.8)** 4 (21.1)**  6 (31.6)* 
 Placebo 16 (80.0) 5 (25.0)** 6 (30.0)** 14 (70.0)# 
Differences between groups  NS NS NS P=0.03 
 
T. forsythia Test 16 (84.2) 4 (21.1)* 6 (31.6)**  6 (31.6)** 
 Placebo 17 (85.0) 5 (25.0)* 8 (40.0)** 14 (70.0)# 
Differences between groups  NS NS NS P=0.04 
      
T. denticola Test 18 (94.7) 5 (26.3)* 7 (36.8)* 7 (36.8)* 
 Placebo 18 (90.0) 5 (25.0)* 11 (55.0)§ 15 (75.0)# 
Differences between groups  NS NS NS P=0.03 
NS=difference between groups is not statistically significant (P>0.05) 
*P<0 .0001; p-values represent longitudinal changes from baseline  
**P<0.005 p-values represent longitudinal changes from baseline  
§P<0.05; p-values represent longitudinal changes from baseline  
#P>0.05; p-values represent longitudinal changes from baseline  
 
 
 
 
 
 
 
 
 
 
35 
 
 
Fig. 1 Flow chart of the study design. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
66 subjects screened 
42 eligible subjects 
 
39 subjects randomized 
20 subjects did not meet inclusion 
criteria, 4 refused to participate 
3 subjects were excluded before 
baseline measurements: 2 subjects 
did not return for unknown 
reasons, 1 subject took systemic 
antibiotics  
Placebo group: 20 received 
allocated intervention 
Test group: 19 received 
allocated intervention 
6-month evaluation: 
clinical/microbiological 
assessment 
3-month evaluation: 
clinical/microbiological 
assessment 
 
No subject missed 
follow-up 
 
No subject missed 
follow-up 
No subject missed 
follow-up 
 
20 subjects were 
analysed 
No subject missed 
follow-up 
 
19 subjects were 
analysed 
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Figure 2.  Prevalence of single species in moderate periodontal pockets in test and 
placebo group at  various time points (number of sites evaluated) 
 
 
Figure 3.  Prevalence of single species in deep periodontal pockets in test and  
placebo group at various time  points (number of sites evaluated) 
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